Erasca Reports Second Quarter 2026 Business Updates and Financial Results
Erasca, Inc. announced encouraging updated clinical data for its ERAS-0015 candidate showing promising efficacy and tolerability in KRAS G12X pancreatic and lung cancers. The company raised $632 million in a recent upsized public offering to advance multiple registration-enabling trials and strengthen its balance sheet. Several key clinical milesto…